Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19395640 | 0.90 | ADRA2A (0.33) | KDM4EALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL19395623 | 0.83 | CYP3A4 (0.40) | — | |
| SCHEMBL13355636 | 0.83 | KDM4E (0.35) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL19395652 | 0.81 | TSHR (0.34) | TSHRADRA2ANISCH | |
| SCHEMBL19395554 | 0.79 | ACHE (0.31) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL19395733 | 0.78 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL19395680 | 0.78 | — | — | |
| SCHEMBL19379356 | 0.78 | — | — | |
| SCHEMBL19395729 | 0.76 | ADRA2A (0.31) | TSHRADRA2ANISCH | |
| SCHEMBL19395654 | 0.75 | POLB (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552798-B2 | Substituted imidazolecarboxamide as Bruton's tyrosine kinase inhibitors | HENAN ZHIWEI BIOMEDICINE CO., LTD. (CN) | 2026-02-17 | — | — | US | disclosed |
| WO-2023055702-A1 | MAIN PROTEASE (M PRO) INHIBITORS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-04-06 | — | — | WO | disclosed |
| US-20220411430-A1 | SUBSTITUTED IMIDAZOLECARBOXAMIDE AS BRUTON'S TYROSINE KINASE INHIBITORS | HENAN ZHIWEI BIOMEDICINE CO., LTD. (CN) | 2022-12-29 | — | — | US | disclosed |
| US-20220411430-A1 | SUBSTITUTED IMIDAZOLECARBOXAMIDE AS BRUTON'S TYROSINE KINASE INHIBITORS | HENAN ZHIWEI BIOMEDICINE CO., LTD. (CN) | 2022-12-29 | — | — | US | disclosed |
| CN-114761399-A | Imidazole carboxamide derivatives as Bruton's tyrosine kinase inhibitors | 河南知微生物医药有限公司 | 2022-07-15 | — | — | CN | disclosed |
| US-11376260-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11376260-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| WO-2021110142-A1 | SUBSTITUTED IMIDAZOLECARBOXAMIDE AS BRUTON'S TYROSINE KINASE INHIBITORS | HENAN NORMAL UNIVERSITY (CN) | 2021-06-10 | — | — | WO | disclosed |
| US-20210106593-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-10842799-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| WO-2001042273-A9 | ASTHMA ASSOCIATED FACTORS AS TARGETS FOR TREATING ATOPIC ALLERGIES INCLUDING ASTHMA AND RELATED DISORDERS | GENAERA CORP (US) | 2002-11-21 | — | — | WO | disclosed |
| EP-1235849-A2 | ASTHMA ASSOCIATED FACTORS AS TARGETS FOR TREATING ATOPIC ALLERGIES INCLUDING ASTHMA AND RELATED DISORDERS | GENAERA CORPORATION (US) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001077104-A1 | BICYCLIC HETEROCYLCES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR PRODUCING THEM | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2001-10-18 | — | — | WO | disclosed |
| WO-2001042273-A2 | ASTHMA ASSOCIATED FACTORS AS TARGETS FOR TREATING ATOPIC ALLERGIES INCLUDING ASTHMA AND RELATED DISORDERS | GENAERA CORPORATION (US) | 2001-06-14 | — | — | WO | disclosed |
| US-5599810-A | ADMINISTERING IN TREATMENT OF BENIGN PROSTATIC HYPERTROPHY, PERIPHERAL VASCULAR DISEASE AND CONGESTIVE HEART FAILURE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-02-04 | — | — | US | disclosed |
| EP-0684949-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-12-06 | — | — | EP | disclosed |
| EP-0684949-A4 | CHEMICAL COMPOUNDS. | SMITHKLINE BEECHAM CORP (US) | 1995-10-13 | — | — | EP | disclosed |
| WO-1994019354-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-09-01 | — | — | WO | disclosed |
| US-4806605-A | Monomers and initiators for group transfer polymerization | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-02-21 | — | — | US | disclosed |
| EP-0276976-A2 | Monomers and initiators for group transfer polymerization | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376260-B2 | Serine/threonine kinase inhibitors | MAP3K1, MAP3K4, MAP4K2 | KDM4E 1621/4885ALDH1A1 3097/4885HPGD 1586/4885 |
| US-10842799-B2 | Serine/threonine kinase inhibitors | MAP3K1, MAP3K4, MAP4K2 | KDM4E 1621/4885ALDH1A1 3097/4885HPGD 1586/4885 |
| US-12552798-B2 | Substituted imidazolecarboxamide as Bruton's tyrosine kinase inhibitors | BTK, LCK, SYK | KDM4E 1746/4885ALDH1A1 3827/4885HPGD 4772/4885 |
| US-20210106593-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K4, MAP4K2 | KDM4E 1621/4885ALDH1A1 3097/4885HPGD 1586/4885 |
| US-20220411430-A1 | SUBSTITUTED IMIDAZOLECARBOXAMIDE AS BRUTON'S TYROSINE KINASE INHIBITORS | BTK, SYK, LYN | KDM4E 844/4885ALDH1A1 3188/4885HPGD 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.